Esperion Therapeutics (ESPR) Invested Capital (2018 - 2025)
Esperion Therapeutics' Invested Capital history spans 8 years, with the latest figure at -$204.7 million for Q4 2025.
- For Q4 2025, Invested Capital rose 29.91% year-over-year to -$204.7 million; the TTM value through Dec 2025 reached -$204.7 million, up 29.91%, while the annual FY2025 figure was -$204.7 million, 29.91% up from the prior year.
- Invested Capital reached -$204.7 million in Q4 2025 per ESPR's latest filing, down from -$137.5 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of -$137.5 million in Q3 2025 to a low of -$410.0 million in Q3 2023.
- Average Invested Capital over 5 years is -$299.5 million, with a median of -$299.3 million recorded in 2021.
- Peak YoY movement for Invested Capital: crashed 4148.05% in 2021, then skyrocketed 62.87% in 2025.
- A 5-year view of Invested Capital shows it stood at -$196.9 million in 2021, then crashed by 64.4% to -$323.8 million in 2022, then skyrocketed by 40.27% to -$193.4 million in 2023, then tumbled by 51.0% to -$292.0 million in 2024, then rose by 29.91% to -$204.7 million in 2025.
- Per Business Quant, the three most recent readings for ESPR's Invested Capital are -$204.7 million (Q4 2025), -$137.5 million (Q3 2025), and -$378.7 million (Q2 2025).